Buys across the board as coverage launched on Ultragenyx and Cara

"Ultragenyx (RARE +3.8%) has a broad and promising pipeline consisting of four therapies for five rare and serious genetic diseases," says Canaccord analyst Salveen Richter, initiating the red-hot recently IPOd stock with a Buy and $85 price target. "We like the orphan-disease-focused strategy for early proof-of-concept, short time-to-clinic, exclusivity and pricing power and particularly the leveragability of this model." He estimates $1B in peak worldwide sales for the company, with high chance of securing regulatory approval. " In addition, we view the preclinical asset (rhPPCA) as a free call option and expect a continued focus on early-stage R&D."

Cowen and Morgan also launch coverage with Buys.

Ahead since its IPO, but a relative slacker compared to RARE, Cara Therapeutics (CARA +2.6%) also rates a Buy from Canaccord with $25 price target. "We expect positive data from three upcoming post-op Ph3 studies in H2/15," says analyst Ritu Baral. "We think ‘845 could gain significant market share and model potential US peak sales of $750M."

Stifel, Janney, and Piper also chime in with Buy ratings.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs